Status:
COMPLETED
HyperArc Registry Study
Lead Sponsor:
Varian, a Siemens Healthineers Company
Conditions:
Brain Metastases
CNS Neoplasm
Eligibility:
All Genders
18+ years
Brief Summary
The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.
Detailed Description
A significant percentage of newly diagnosed cancer patients will develop brain metastases. For many of these patients, stereotactic radiosurgery (SRS) is recommended as a primary treatment option. Con...
Eligibility Criteria
Inclusion
- Received or scheduled to receive treatment using the HyperArc treatment method
- Age of legal adult according to local law
- Signed informed consent form, or, informed consent waived by the local ethics board/institutional review board
Exclusion
- None, apart from not meeting Inclusion Criteria
Key Trial Info
Start Date :
March 31 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2025
Estimated Enrollment :
968 Patients enrolled
Trial Details
Trial ID
NCT05270707
Start Date
March 31 2022
End Date
March 31 2025
Last Update
September 24 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama
Birmingham, Alabama, United States, 35233
2
Icon Cancer Centre Canberra
Bruce, Australian Capital Territory, Australia, 2617
3
Icon Cancer Centre Greenslopes
Greenslopes, Queensland, Australia, 4120
4
Icon Cancer Centre Maroochydore
Maroochydore, Queensland, Australia, 4558